Related Experiment Video
Updated: May 10, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Pediatric blepharokeratoconjunctivitis: review of epidemiology, pathophysiology, and current treatments
Rija Awan1, Shama Khan2, Wajid Ali Khan2
1University of Michigan Medical School, Ann Arbor, Michigan, USA.
Insights
Pediatric blepharokeratoconjunctivitis (BKC) is a chronic eye condition often underdiagnosed. Integrated management approaches achieve high remission rates, with new treatments like lotilaner offering improved efficacy.
Area of Science:
- Ophthalmology
- Pediatric Eye Care
Background:
- Pediatric blepharokeratoconjunctivitis (BKC) is a chronic inflammatory condition affecting the eyelids, conjunctiva, and cornea.
- It is frequently underdiagnosed and can lead to vision-threatening complications.
Purpose of the Study:
- To offer a comprehensive review of pediatric BKC epidemiology and clinical characteristics.
- To explore the underlying pathophysiology and assess emerging therapeutic strategies for BKC.
Main Methods:
- Literature review of epidemiological data, clinical features, pathophysiology, and treatment strategies for pediatric BKC.
- Analysis of recent clinical evidence and FDA-approved treatments.
Main Results:
- Remission rates of approximately 95% are achievable with integrated management, including antibiotics, corticosteroids, immunosuppressants, and lid hygiene.
- The FDA has approved 0.25% lotilaner ophthalmic solution for Demodex blepharitis, showing safety and efficacy with twice-daily application over six weeks.
Conclusions:
- Pediatric BKC is a chronic, recurrent condition requiring early diagnosis and patient education.
- Standardized treatment protocols are lacking, highlighting the need for continued research to prevent severe visual outcomes.
Purpose Of Review:
This review aims to provide a comprehensive overview of the epidemiology and clinical features of pediatric blepharokeratoconjunctivitis (BKC), with a focus on elucidating the underlying pathophysiology and evaluating new therapeutic strategies.
Recent Findings:
Ongoing research continues to refine the management of pediatric BKC. Recent evidence suggests that disease remission can be achieved in approximately 95% of cases through an integrated approach involving topical or systemic antibiotics, corticosteroids, topical immunosuppressants, and lid hygiene. Notably, a significant advancement in the treatment of Demodex blepharitis is the FDA approval of 0.25% lotilaner ophthalmic solution, which has demonstrated safety and efficacy with twice-daily application over six weeks.
Summary:
Pediatric blepharokeratoconjunctivitis is a chronic inflammatory condition affecting the eyelids, conjunctiva, and cornea. It is underdiagnosed and associated with significant vision-threatening complications. While there is no established consensus on the most effective therapeutic strategy, management currently includes lid hygiene, topical/systemic antibiotics, corticosteroids, immunosuppressants, lubricants, and dietary supplements. Challenges arise from its chronicity, recurrence, and lack of standardized treatment protocols. This underscores the importance of early diagnosis, education, and continued research on treatment methods to prevent severe outcomes.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Accessory Structures of the Eye

